Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 29HR+/HER2- Advanced Breast Cancer 3Breast Cancer Metastatic 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Esophageal Squamous Cell Carcinoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

Trastuzumab 30pertuzumab 16Docetaxel 16pyrotinib 11Paclitaxel 7Carboplatin 5Capecitabine 5Ado-Trastuzumab Emtansine 4tucatinib 3trastuzumab deruxtecan 2atezolizumab 2Protons 2Fulvestrant 2pegfilgrastim 1palbociclib 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-positive Breast Cancer × dalpiciclib × Clear all
NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡